Cellivery Therapeutics financials at a glance
| Year | Year | 2018 | 2019 | 2020 | 2017 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
₩4.51B | ₩0.00M | ₩761.57M | ₩2.77B | ₩3.87B | ₩23.16B | ₩0.00M |
| GM % | Gross Margin % |
|
32.97% | 0.00% | -97.65% | 28.47% | 0.62% | -1.93% | 0.00% |
| OM | Operating Margin |
|
-90.92% | 0.00% | 0.00% | -125.54% | 0.00% | -293.70% | 0.00% |
| EPS | Earnings Per Share |
|
₩0.00 | ||||||
| Div. | Dividends |
|
₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| PR % | Payout Ratio % |
|
0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sha. | Shares |
|
7.61m | 7.82m | 32.74m | 0m | 34.67m | 17.33m | 0m |
| OCF | Operating Cash Flow |
|
₩-2639.29M | ₩0.00M | ₩-16096.64M | ₩-514.95M | ₩-22744.26M | ₩-56381.14M | ₩0.00M |
| FCF | Free Cash Flow |
|
₩-3304.02M | ₩0.00M | ₩-17304.65M | ₩-846.38M | ₩-27333.81M | ₩-74029.81M | ₩0.00M |
| FCFS | Free Cash Flow Per Share |
|
₩-321.65 | ₩0.00 | ₩-538.04 | ₩-314.42 | ₩-812.81 | ₩-2959.84 | ₩0.00 |